Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2006

View Archived Issues

Genzyme presents overview of quarterly activities

Study results detail entecavir efficacy in hepatitis B

Clevudine effective in hepatitis B patients treated for 1 year

Objective responses seen with A-007 in cutaneous cancer metastases

Spotlight on clinical progress of OROS-Hydromorphone for pain syndromes

Chugai updates recent developments

Prous Science online journals add multimedia component

Dendritic RNA transport granule proteins postulated to play a role in nociception

Sirna and GlaxoSmithKline begin programs in asthma and RSV

Acenta developing NAAG peptidase inhibitors for brain injury

Remoxy begins phase III program

Manhattan to study oleoyl-estrone for obesity in phase IIa study

Formulation difficulties for Manhattan's topical PTH (1-34)

OxyPharma obtains funding to advance ROB-803 into phase II

Heparins interfere with P-selectin binding and block metastasis

Nonproprietary name lorcaserin hydrochloride approved for APD-356

SkyePharma and Kos sign agreement for Flutiform

Celtic cleared in U.K. to begin phase II study of TA-NIC

Topline data support use of Frova in prevention of menstrual migraine

CancerVax and Micromet complete merger

Positive phase III findings for Evamist

Phase III trial of H5N1 influenza pandemic vaccine cleared to begin in Spain

NDA submission for Gestiva for prevention of preterm birth

PBT-2 well tolerated in phase I program

Novel analgesic agents imparted in recent patent literature

New therapeutics for neurological disorders reported in recent patents

Enjuvia now available in U.S.

Preliminary clinical results on GTI-2040 published

New patents cover novel antidiabetic agents

Snapshots of potential treatments for uveal melanoma

Novel neuroprotective strategies in glaucoma therapeutics - Part I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...